Condition: Tricuspid Regurgitation · Tricuspid Valve Insufficiency · Cardio-Renal Syndrome · Sponsor: Robert Bosch Medical Center
The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.
This description comes directly from the study's public registry record.
Andrea Schwab · 071181010 · Sekretariat-Nephrologie@rbk.de
Always discuss trial participation with your own doctor first.
| Robert Bosch Hospital | Stuttgart, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07464106